Abstract
Cyclophosphamide (CP) is an alkylating cytostatic compound, which is activated to its cytotoxic form in the liver [1]. Since the therapeutic range of CP in the treatment of human tumours, is small like other cytostatics, a constant high bioavailability is essential for its oral administration. Although CP has become one of the most widely used cytostatics [2], there do not appear to have been any bioavailability investigations providing the necessary information. The development of a very sensitive gas chromatographic analytical method has now permited investigation of the pharmacokinetics of oral CP in conventional clinical doses [3, 4, 5, 6].
This is a preview of subscription content, log in via an institution to check access.
References
Brock N, Hohorst H-J (1977) The problem of specificity and selectivity of alkylating cytostatics: studies on N-2-Chloroethyl-amidooxazaphosphorines. Z Krebsforsch 88: 185–215
Hill DL (1975) A review of cyclophosphamide. C.C. Thomas, Springfield, Illinois, USA
Gourmel B, Gisselbrecht C, Marty M, Colvin M, Dreux C, Boivon M (1982) Simultaneous detection of cyclophosphamide, ifosfamide, carboxyphosphamide and phosphoramide mustard using derivatization with heptafluoro acetic anhydrid. Proceedings 13th International Cancer Congress, Seattle, USA. Abstract 843, p 148
Juma FD, Rogers HJ, Trounce JR (1979) Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration. Br J Clin Pharmacol 8: 209–217
D'Incalci M, Bolis G, Facchinetti T, Mangioni C, Morasca L, Morazzoni P, Salmona M (1979) Decreased half-life of cyclophosphamide in patients under continual treatment. Eur J Cancer 15: 7–10
Slee PHTh Jr, de Bruijn EA, Driessen OMJ, Hermans J, van Oosterom AT (1983) Pharmacokinetics of cytostatic drugs used in the CMF-regimen. Anticancer Res 3: 269–272
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wagner, T., Fenneberg, K. Bioavailability of cyclophosphamide from oral formulations. Eur J Clin Pharmacol 26, 269–270 (1984). https://doi.org/10.1007/BF00630298
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00630298